key: cord-1000783-ghhtj9wc
authors: Ignatius, Elisa H; Wang, Kunbo; Karaba, Andrew; Robinson, Matthew; Avery, Robin K; Blair, Paul; Chida, Natasha; Jain, Tania; Petty, Brent G; Siddiqui, Zishan; Melia, Michael T; Auwaerter, Paul G; Xu, Yanxun; Garibaldi, Brian T
title: Tocilizumab for the treatment of COVID-19 among hospitalized patients: A matched retrospective cohort analysis
date: 2020-12-28
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa598
sha: 227a6ff6ab1ed50cf90fafefa9496cec629ded70
doc_id: 1000783
cord_uid: ghhtj9wc

BACKGROUND: There is currently no single treatment that mitigates all harms caused by SARS-CoV-2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as adjunctive immune-modulating therapy. METHODS: This was an observational, retrospective study of hospitalized adult patients with confirmed COVID-19. The intervention group comprised patients who received tocilizumab; the comparator arm was drawn from patients who did not receive tocilizumab. The primary outcome was all-cause mortality censored at 28 days; secondary outcomes were all-cause mortality at discharge, time to clinical improvement, and rates of secondary infections. Marginal structural Cox models via inverse probability treatment weights were applied to estimate the effect of tocilizumab. Time-dependent propensity score matching method was used to generate a 1:1 match for tocilizumab recipients; infectious diseases experts then manually reviewed these matched charts to identify secondary infections. RESULTS: This analysis included 90 tocilizumab recipients and 1669 controls. Under the marginal structural Cox model, tocilizumab was associated with a 62% reduced hazard of death (aHR 0.38, 95% CI: 0.21-0.70) and no change in time to clinical improvement (aHR: 1.13, 95% CI: 0.68-1.87). The 1:1 matched dataset also showed a lower mortality rate (27.8% vs. 34.4%) and reduced hazards of death (aHR: 0.47, 95% CI: 0.25-0.88). Elevated inflammatory markers were associated with reduced hazards of death among tocilizumab recipients compared to controls. Secondary infection rates were similar between the two groups. CONCLUSIONS: Tocilizumab may provide benefit in a subgroup of patients hospitalized with COVID-19 who have elevated biomarkers of hyperinflammation, without increasing the risk of secondary infection.

In December 2019, reports of what would soon be labeled as coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 began to emerge. As of November 19, 2020, worldwide infections are estimated at 56.4 million and deaths at 1.4 million. The United States is the current epicenter of the global pandemic, with over 11.5 million cases and 250,000 deaths. 1 Elevations in interleukin-6 (IL-6) and C-reactive protein (CRP) have been associated with poor outcomes from COVID-19. [2] [3] [4] This has led to the hypothesis that a second illness phase seen in a minority of patients is a hyperinflammatory state, 5 analogous to -cytokine release syndrome‖ (CRS) with chimeric antigen receptor (CAR) T-cell therapy, 6 which is also seen in both SARS-CoV-1 and MERS-CoV infections. 7 In the hyperinflammatory states associated with CAR-T therapy and certain rheumatologic diseases, anti-IL6 therapy has proven beneficial. [8] [9] [10] [11] Though some studies show that IL-6 levels in severe COVID-19 are lower than in other causes of ARDS, 12 there remains interest in using immunomodulatory therapies to dampen the inflammatory cascade in affected patients.

Treatment for COVID-19 is evolving as therapeutic trials progress. Remdesivir, an antiviral, may shorten time to recovery, particularly when used early in the disease course. 13, 14 Dexamethasone reduced mortality in COVID-19 among those requiring supplemental oxygen, 15 and a meta-analysis of corticosteroid trials found reduced mortality, regardless of oxygen support or symptom duration. 16 Numerous other immunomodulatory drugs are currently under investigation. [17] [18] [19] Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor (IL-6R), has been used to treat rheumatologic diseases 20 and CRS due to CAR-T therapy. 10 Given its relative global availability, tocilizumab was used off-label at many sites in the first few months of the COVID-19 pandemic.

Several recent studies have yielded conflicting results about the effects of tocilizumab in COVID-19, including secondary infection risk. [21] [22] [23] [24] [25] [26] [27] [28] [29] Careful retrospective analyses of the off-label use of tocilizumab can assist in understanding whether the drug has utility. This study aims to describe outcomes including secondary infection risk and identify clinical and laboratory features that predict A c c e p t e d M a n u s c r i p t 5 benefit among hospitalized patients with COVID-19 and evidence of a hyperinflammatory state who received off-label tocilizumab within the Johns Hopkins Health System (JHHS).

This is an observational, retrospective, non-randomized study of adult patients (>18 years) with confirmed COVID-19, hospitalized within JHHS between March 15 and June 27, 2020. JHHS is a 5-hospital system in the Baltimore/Washington DC area with approximately 2300 beds. COVID-19 was diagnosed via SARS-CoV-2 RNA detection on polymerase chain reaction (PCR) in nasal swab, nasopharyngeal swab, or bronchoalveolar lavage (BAL). The intervention group was patients who received tocilizumab for off-label treatment of COVID-19, and the comparator arm was drawn from patients with COVID-19 who did not receive tocilizumab. Patients were excluded if they were less than 18 years old, or if they died or were discharged within 24 hours after hospitalization. Some of the included patients have been part of prior analyses. 4

The COVID-19 Precision Medicine Analytics Platform (PMAP) Registry (JH-CROWN) includes clinical and laboratory data from all patients admitted to JHHS with suspected or confirmed SARS-CoV-2 infection. Data were extracted from the electronic medical record and also included Research Electronic Data Capture (REDCap) data from manual chart abstraction. A group of infectious diseases specialists adjudicated incident infections and pre-existing immunosuppression (use of corticosteroid or chemotherapy, history of solid organ or bone marrow transplant). Cases in A c c e p t e d M a n u s c r i p t 6 which there was uncertainty were discussed jointly by all adjudicating infectious diseases specialists before reaching a final decision.

Off-label tocilizumab administration at JHHS requires approval of the 5-member JHHS Formulary COVID-19 Drug Approval Committee. Patients are potentially eligible to receive tocilizumab if they meet pre-specified criteria, including progressive hypoxemia, vital sign instability, and elevated inflammatory markers (Supplementary Table S1 ). When a clinician wants to prescribe tocilizumab, a request is submitted for consideration to the designated member at each hospital on the JHHS Formulary COVID-19 Drug Approval Committee, who then presents the case request by conference call to the other available Committee members. If approval is obtained, patients receive a single intravenous dose of tocilizumab, usually 8 mg/kg (range 6-8 mg/kg) not to exceed 800 mg. 10 ,20,30

The primary outcomes were all-cause in-hospital mortality, right-censored at 28 days and allcause mortality at time of discharge. The secondary outcome was clinical improvement, defined as a decrease of two points in the World Health Organization (WHO) Ordinal Scale for Clinical Improvement or hospital discharge. 31 Secondary infection rate was also analyzed as a safety outcome. [32] [33] [34] [35] [36] [37] 

Given the non-randomized nature of tocilizumab receipt, marginal structural Cox models 38 via inverse probability treatment weights (IPTW) were applied to estimate the treatment effect of tocilizumab on the primary outcomes by estimating the hazards of death after adjusting for the Charlson Comorbidity Index (CCI). Time-dependent (varying) covariates included clinical measures of disease severity, such as SpO 2 /FiO 2 (S:F), respiratory rate, temperature, systolic blood pressure, diastolic blood pressure, pulse, oxygen supplementation device, and code status (whether a patient had a do-not-resuscitate (DNR)/do-not-intubate (DNI) order). S:F was selected since it can be calculated without obtaining an arterial blood gas (not available on all patients), and has a good correlation with more traditional measure of ARDS severity such as PaO 2 /FiO 2 (P:F). 39 Time-varying laboratory parameters included C-reactive protein (CRP), white blood cell (WBC) count, absolute lymphocyte count (ALC), hemoglobin (Hgb), albumin, alanine aminotransferase (ALT), glomerular filtration rate (GFR), D-dimer, ferritin and IL-6. Missing values were imputed using multiple imputation by chained equations (MICE) with the predictive mean matching method. 40 To assess the adjusted hazard ratio of tocilizumab treatment on death, a set of demographics and clinical variables were included in Cox regression models.

Clinical improvement was defined as live discharge from the hospital without worsening of WHO score, or at least a two-point decrease in WHO score during hospitalization. A marginal structural Cox model was applied with the same set of covariates adjusted for the bias of both treatment exposure and death as a censoring event.

A c c e p t e d M a n u s c r i p t 8 Due to the large size of the comparator arm, manual chart review for adjudication of all incident infections was not feasible. Therefore, we used a time-dependent propensity score matching method to balance between treatment and control arms by making them similar (only randomly different) regarding pre-specified covariates (see Supplement for details). After matching, these 180 patients (90 tocilizumab recipients, 90 matched controls) were compared for their survival over time and risk of secondary infection.

Post-hoc analyses included duration of ventilation and concomitant medication administration (remdesivir, dexamethasone) and were compared using a Welch two-sample t-test. Data were analyzed using R version 3.6.2. 41 Baseline characteristics between the tocilizumab recipients and all (unmatched) controls were numerically different (column 2, Table 1 ). Tocilizumab recipients were more frequently male, with longer hospitalizations, more severe respiratory failure, and more comorbidities (including 5.6% versus 1.8% with history of solid organ transplantation). After matching using both the marginal structural Cox model and propensity score, balance on key covariates was improved ( Table 1) . There Table S2 ).

In the unadjusted data set, tocilizumab recipients had a higher mortality rate (27.8% vs.

11.0%). However, using the marginal structural Cox model, patients who received tocilizumab had a 62% reduced hazard of death at 28 days (aHR: 0.38, 95% CI: 0.21-0.70, p=0.002), compared with controls ( Table 2 ). This was also true for the 1:1 matched dataset, which showed a lower mortality rate in tocilizumab recipients (27.8% vs. 34.4%) and reduced hazards of death (aHR: 0.47, 95% CI: 0.25-0.88, p=0.02) (Figure 2 ). To analyze any differential effects of tocilizumab on mortality within subgroups, patients were separated into strata of various demographics, vital signs, and laboratory results at time of hospitalization. Grouping thresholds were selected based on a heuristic method as well as clinical knowledge. Certain subgroups appeared to receive greater mortality benefit with tocilizumab than others, including male gender, age over 55 years (particularly 55-65), few comorbidities (CCI <5), and more normal vital sign values (pulse < 100, MAP ≥ 60, temperature < 38.3°C). Mortality benefit was seen across all strata of S:F groupings. Elevated ferritin (>800 ng/mL), albumin level (≥ 3 g/dL), ALT level (≥ 30 U/L), and WBC count (≥ 12 x10 3 /mm 3 ), as well as lower CRP (< 16 mg/dL), and D-dimer both <1 and ≥ 4 mg/L were associated with reduced hazards of death among tocilizumab recipients compared to non-recipients. Among patients with IL-6 >55 pg/mL, tocilizumab was associated with reduced hazard of death (aHR: 0.34, 95% CI: 0.18 -0.64, p=0.0008).

When mortality data were censored only at time of death or discharge (rather than 28 days), the effect was mildly attenuated due to few patients remaining at risk for the outcome (aHR: 0.39, 95% CI: 0.21-0.71, p=0.002) (Supplementary Table S3) . 

This study suggests that tocilizumab may be beneficial for patients hospitalized with COVID-19 who have elevated biochemical markers of inflammation. 22, 42, 43 Hazard of death was significantly lower among tocilizumab recipients, using both a marginal structural Cox model and traditional propensity score matching. Men above 55 years of age with few comorbidities and moderate elevation in inflammatory markers were among those who benefited most. There was no difference between tocilizumab recipients and controls in time to clinical improvement or risk of secondary infection. This study has several strengths. Tocilizumab approval within JHHS was based on set institutional criteria, which may have mitigated some effect of provider preference. While other retrospective studies matched on baseline characteristics alone, 28 our study applied a marginal structural Cox model to account for disease progression before the receipt of tocilizumab and included a large number of significant demographic, clinical, and laboratory covariates. Length of follow-up was longer than some studies and showed that the mortality benefit of tocilizumab extends out to at least 28 days. We used robust statistical methods to address confounding by indication, including two different matching methods that yielded similar results. Adjudication of secondary infection was A c c e p t e d M a n u s c r i p t 11 performed by a panel of infectious disease experts, using a set of guidelines-based criteria and showed no excess infections with both stringent and liberal definitions. [32] [33] [34] [35] [36] Overall, our findings converge with those of several other published retrospective studies.

Two studies of tocilizumab with concurrent controls found reduced mechanical ventilation and death. 22,44 Another study using historical controls found higher survival, recovery, and respiratory function. 43 A single arm study of mostly intubated patients found that clinical and laboratory parameters improved after tocilizumab administration. 45 A study of mechanically ventilated patients found a 45% reduction in hazards of death, despite more secondary infections in tocilizumab recipients, as well as improvement on the WHO ordinal scale. 37 A smaller study found numerical trends that were similar to ours, but perhaps due to the smaller sample size results were not statistically significant. 23 Two meta-analyses have yielded conflicting results about the efficacy of tocilizumab in reducing COVID-19 mortality. 46, 47 There are now press-release results available for two sponsor-initiated tocilizumab randomized controlled trials, and published results of three investigator-initiated trials. Though the first sponsored trial of 450 participants with SpO2 <94% found no benefit in clinical status or mortality, time to discharge was 8 days shorter for tocilizumab recipients; it remains unclear how ill patients were at inclusion. 27 A subsequent sponsored trial, which intentionally enrolled minority racial and ethnic groups, found that receipt of tocilizumab was associated with 44% reduction in the composite outcome of death or need for mechanical ventilation (12.2% versus 19.3% at day 28). 26 A recently-published open-label randomized trial of patients with P:F 200-300 found no effect of tocilizumab on clinical worsening; however, only ICU-eligible patients were included, mortality rates were low (0.8% at day 14, 2.4% at day 30), and 12 of 66 control patients later received tocilizumab.

Additionally, patients in the control arm were less sick (based on CRP, IL-6, ferritin, D-dimer) and treated more often with antivirals compared with tocilizumab recipients, despite randomization. 25 A second open-label randomized trial of patients with moderate to severe pneumonia requiring at least 3L oxygen via nasal cannula found no effect of tocilizumab on clinical worsening; benefit was seen at day 14 but not at day 28. 24 Of note, this study recruited less ill patients (non-ICU, on nasal cannula A c c e p t e d M a n u s c r i p t 12 only), 47% of tocilizumab recipients received a second dose on day 3, and control arm patients received more immunomodulatory therapies including anakinra, eculizumab, and dexamethasone. In the only published randomized, double-blind, placebo-controlled trial to date, tocilizumab use was not effective for preventing intubation or death. However, the trial was small (243 patients) and the confidence intervals for efficacy comparisons were wide. 29 All three published trials found lower rates of secondary infection in the tocilizumab arms. Studies of similar drugs targeting inflammatory cytokines have yielded mixed results [48] [49] [50] and highlight the need for additional well-designed, masked, randomized controlled trials.

Similar to other studies, we found that elevated inflammatory markers were associated with worse outcomes overall ( Supplementary Table S5 ), 2,51 including higher mortality for all patients with IL-6 ≥ 55 pg/mL. 52, 53 It remains unclear whether IL-6 is a marker of disease progression or directly contributes to pathogenesis in COVID-19. 54 We found that for patients with IL-6 ≥ 55 pg/mL there was a 66% reduction in hazard of death among those who received tocilizumab compared with controls. The average IL-6 level of treated patients in the published randomized trials of tocilizumab ranged from 23.6 pg/ml to 50.4 pg/ml. 25,29 In our study, 89% of treated patients had an IL-6 level above 55 pg/ml with a mean level of 865.6pg/ml and a median level of 239.8 pg/ml. The fact that our study showed a robust mortality benefit in contrast to these recent randomized trials may indicate that elevated IL-6 levels, likely a proxy for a hyperinflammatory state, are necessary in order for patients to benefit from tocilizumab.

From a heterogeneous cohort, our matching generated comparable groups in terms of numerous covariates relevant to the endpoints of death and clinical improvement. However, there could be unmeasured variables that biased our treatment effect estimates. Though our study and some others have not found excess secondary infection risk, this observation may not be generalizable 55 and the risk of certain infectious complications, such as herpesvirus reactivation, may be uniquely elevated A c c e p t e d M a n u s c r i p t 13 after tocilizumab. 56 Additionally, larger tertiary care centers where these observational studies are taking place may have more robust infectious disease expertise to help mitigate these infectious risks and prevent ensuing deaths. Therapeutic guidance at Johns Hopkins evolved over the study period, which could have introduced biases of secular trends. Infection fatality rates due to COVID-19 have overall declined since these data were collected, which may limit direct translation of these observations into clinical practice. To address secular trends in treatments and mortality, controls were selected from the same time period as tocilizumab recipients and both arms had a similar tempo of recruitment over time (Supplementary Figure S1) . Nonetheless, most of the included patients received tocilizumab before data supporting remdesivir and dexamethasone had emerged. The treatment landscape for COVID-19 is dynamic and the role of tocilizumab in combination with dexamethasone and remdesivir remains to be elucidated. Additionally, tocilizumab was given at a median 2.6 days after admission in our study, but the optimal timing of administration in the disease course remains unknown.

We found that among patients hospitalized with COVID-19 and elevated biochemical markers suggestive of a hyperinflammatory state, the administration of tocilizumab reduced the hazard of death by 62%. Particular subgroups who appeared to benefit included older males with few comorbidities and elevated inflammatory markers such as IL-6. There was no evidence of an increased risk of hospital-acquired infection among tocilizumab recipients. The optimal dosing strategy, timing of administration and combined use with other therapeutics remains to be elucidated.

While we await the results of additional randomized trials, our study has identified clinical and laboratory features that predict potential benefits from tocilizumab in hospitalized patients with COVID-19 and evidence of hyperinflammation. 

The institutional review boards at each of the 5 participating hospitals approved this study as minimal risk and waived consent requirements.

PGA is on the DSMB for Humanigen. RKA has received grant/study support from: Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. TJ has a consultancy with Takeda oncology and is on the advisory board for CareDx and Bristol Myers Squibb. MTM reports research grants to his institution from Gilead Sciences. BGP has received funding from Bristol Myers Squibb and AstraZeneca. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S Armed Forces. 

Johns Hopkins Coronavirus Resource Center

Viral and host factors related to the clinical outcome of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study

Dysregulation of Immune Response in Patients With Coronavirus

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?

Tocilizumab in systemic juvenile idiopathic arthritis in a realworld clinical setting: results from 1 year of postmarketing surveillance follow

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Chimeric antigen receptor T-cell therapyassessment and management of toxicities

Is a -Cytokine Storm‖ Relevant to COVID-19?

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Effect of Dexamethasone in Hospitalized Patients with COVID-19 -Preliminary Report

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Provides an Update on the Phase III COVACTA Trial of Actemra/RoActemra in Hospitalised Patients with Severe COVID-19 Associated Pneumonia

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group

AST Infectious Diseases Community of Practice

virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Identifying Healthcare-Associated Infections ( HAI ) for NHSN Surveillance

AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures

Comparison of the SpO2/FIO2 ratio and the

PaO2/FIO2 ratio in patients with acute lung injury or ARDS

Multivariate imputation by chained equations in R

R: A language and environment for statistical computing

Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Efficacy of tocilizumab in patients with COVID-19

ARDS undergoing noninvasive ventilation

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Tocilizumab for severe COVID-19: a systematic review and meta-analysis

Efficacy of tocilizumab treatment in severely ill COVID-19 patients

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients

Anakinra for severe forms of COVID-19: a cohort study

IL-6 inhibitors for treatment of rheumatoid arthritis: past

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies

A c c e p t e d M a n u s c r i p t 15 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t